Trial Profile
A Phase 1, Double-Blind, Placebo-Controlled Study of Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Cimaglermin alfa (Primary)
- Indications Heart failure; Left ventricular dysfunction
- Focus Adverse reactions; First in man
- Sponsors Acorda Therapeutics
- 12 Mar 2018 Results assessing the safety and efficacy of cimaglermin presented at the 67th Annual Scientific Session of the American College of Cardiology
- 18 Mar 2017 Results (n=2) investigating cases of hepatotoxicity from two phase 1 trials (NCT01944683 and NCT01258387) meeting Hy's Law criteria, presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 10 Mar 2015 According to an Acorda Therapeutics media release, data presented at the American College of Cardiology 64th Annual Scientific Session and Expo (ACC) 2015.